BioCentury
ARTICLE | Regulation

June 8 Quick Takes: Enavate, Venrock back Upstream’s $200M round

Plus: FDA panel backs nirsevimab for RSV and updates from Repare, Pieris  

June 8, 2023 10:34 PM UTC

Upstream Bio Inc. intends to conduct registrational Phase II studies of lead candidate UPB-101 with a new $200 million round led by Enavate Sciences and Venrock Healthcare Capital Partners. The biotech said it is developing its TLSPR-targeting mAb to treat asthma and chronic rhinosinusitis with nasal polyps. Joining the lead investors were new backers Bain Capital Life Sciences and Wellington Management, as well as the investors from Upstream’s $200 million series A. Patient Square Capital launched Enavate last year.

FDA’s Antimicrobial Drugs Advisory Committee voted 21-0 to recommend the use of nirsevimab from AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and  Sanofi (Euronext:SAN; NYSE:SNY) to prevent RSV in newborns and infants and 19-2 to support the mAb’s use in toddlers. The PDUFA data for the BLA is in 3Q. In May, a committee voted in favor of approving Abrysvo, an RSVpreF maternal vaccine, from Pfizer Inc. (NYSE:PFE), which has a PDUFA date in August. Nirsevimab is approved in Canada, the EU and the U.K. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article